Netherlands· NL-b0dabe409114
Megalotect 100 E/ml oplossing voor infusie
A cytomegalovirus immunoglobulin product containing humaan cytomegalovirus immunoglobuline, registered in Netherlands by Biotest Pharma GmbH. The same ATC class is registered in 9 of our 19 countries.
Checked against CBG-MEB (Netherlands) on
Informational only — not a medical device.
Where it is registered
Cytomegalovirus immunoglobulin is registered in 9 of 19 countries.
Countries holding a registration under ATC J06BB09 (cytomegalovirus immunoglobulin), each read from that country’s own register.
- This record: Netherlands, from CBG-MEB (Netherlands)
- 5 of them publish a price we can compare per daily dose
Cytomegalovirus immunoglobulin · ATC J06BB09
9 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Finlandprice
- Ireland
- Netherlands
- Polandprice
- Switzerlandprice
- United Kingdom
The record
At a glance
CBG-MEB (Netherlands)- Active substance
- HUMAAN CYTOMEGALOVIRUS IMMUNOGLOBULINE
- Manufacturer
- Biotest Pharma GmbH
- Country
- Netherlands (NL)
- ATC code
- J06BB09
- ATC class
- Cytomegalovirus immunoglobulin
- Reimbursed
- Not published by this register
- Source register
- CBG-MEB (Netherlands)
- Last checked
- September 29, 2026
Packs & prices · 1
- cbg_meb_id123161
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Cytomegalovirus immunoglobulin in 7 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- BelgiumIvegam-CMV 100 mg/mlCentrale Afdeling Voor Fractionering - Departement Central De Fractionnement
- United KingdomCytomegalovirus immunoglobulin human 3g powder for solution for infusion vialsScottish National Blood Transfusion Service
- GermanyCytotect CpBiotest Pharma Gmbh
- IrelandMegalotect 100 U/mL solution for infusionBiotest Pharma GmbH
- PolandMegalotect CPBiotest Pharma GmbH
- SpainMEGALOTECT 100 U/ML SOLUCION PARA PERFUSIONBiotest Pharma Gmbh
- CanadaCYTOGAMKI BIOPHARMA LLC
Authorised across Europe · EMA
The same active substance is authorised in 17 EEA countries. Names it is sold under:
- Austria · Cytotect Cp
- Belgium · Megalotect
- Czechia · Cymvigo
- Germany · Cytotect Cp
- Spain · Megalotect
- United Kingdom (Northern Ireland) · Cytotect Cp
- Greece · Megalotect Cp
- Croatia · Cytotect Cp
- Hungary · Cytotect Cp
- Ireland · Megalotect
- Italy · Cytomegatect
- Lithuania · Cymvigo
- Poland · Megalotect Cp
- Portugal · Megalotect Cp
- Romania · Cytotect Cp
- Slovenia · Megalotect
- Slovakia · Cytotect
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of CBG-MEB (Netherlands). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/8432ebc1-ae4c-46a4-b229-78ea53c6b616 GET /v1/drugs/8432ebc1-ae4c-46a4-b229-78ea53c6b616?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Oplossing voor infusie",
"route": "Intraveneus gebruik",
"soort": "RVG",
"source": "cbg_meb",
"smpc_url": "https://www.geneesmiddeleninformatiebank.nl/smpc/h123161_smpc.pdf",
"strength": null,
"atc_label": "Cytomegalovirus Immunoglobulin",
"detail_url": "https://www.geneesmiddeleninformatiebank.nl/nl/rvg123161",
"excipients": [
"GLYCINE (E 640)",
"WATER VOOR INJECTIE"
],
"substances": [
"HUMAAN CYTOMEGALOVIRUS IMMUNOGLOBULINE"
],
"leaflet_url": "https://www.geneesmiddeleninformatiebank.nl/bijsluiters/h123161.pdf",
"authorised_at": "2018/10/18",
"procedure_number": "DE/H/4905/001",
"dispensing_status": "Uitsluitend recept",
"registration_number": "123161",
"additional_monitoring": "N"
}See everything about cytomegalovirus immunoglobulin.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.